Join Our Mailing List
Please enter your contact details below in order to receive regular updates and discount offers for this conference.
Who Should Attend
- Pharmaceutical Companies
- Specialist Repositioning Companies
- Contract Research Organizations
- Mid Cap/SME Biotechs
- Government/Regulatory Bodies
- Academic/Research Institutes
- NGOs/Public Health
VPs, Directors, Managers & Associates responsible for:
Join us in Chicago, where we will highlight the latest developments in the fields of drug repositioning, repurposing and rescue. This conference continues to serve as a global meeting place for those engaged in efforts to further drug development through new means of collaborations, including patient advocacy efforts and industry/academic/government cooperation.
Key Themes at This Year's Conference
Other Topics Covered Include
|► INTELLECTUAL PROPERTY issues relating to new use of known drugs||► TOOL SETS for identifying repositioning opportunities|
|► REGULATORY issues and legal frameworks for drug repositioning||► Drug Repositioning for NEGLECTED DISEASES|
|► REPURPOSING 2.0 – internet-based efforts driven by patients||► Re-tasking currently marketed drugs through COMBINATION THERAPIES|
|► TECHNICAL INNOVATIONS & challenges of drug repositioning||► COMPUTATIONAL APPROACHES to drug repositioning|
|► PAYER PERSPECTIVES on repositioning|
WHAT PAST ATTENDEES HAVE TO SAY ABOUT THIS CONFERENCE
More About Drug Repositioning, Repurposing and Rescue
Drug repositioning has emerged as a potentially cost-effective and quicker alternative to provide new drugs for pharmaceutical companies’ waning pipelines. Approved drugs have already met with the FDA’s approval therefore, the early stages of drug development can be bypassed. By mining existing drugs for new uses, researchers can focus instead on the clinical testing portion of the process. This shortens the development timeline and gets new treatments to patients faster. With new technologies and approaches, drug repositioning has become more streamlined and less accidental than it was in the past. By using a more systematic approach, existing compounds are being tested for both common and neglected diseases faster and with more success.